ÂÜÀòÂÒÂ×

David brings his experience translating new technologies into clinical therapies. Prior to founding Acrigen, David founded and was the CSO of Redwood Biosciences, an antibody-drug conjugate company that was acquired by Catalent Pharma Solutions where he then served as Global Head of R&D.